Tools chosen: polymarket_direct polymarket_related kalshi_related claude_news claude_news gdelt_news wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Polymarket threshold question on CDC-confirmed 2026 US measles cases reaching 10,000 — roughly 4x the 2025 record (~2,300-2,800) and far above any year since 1992. The key empirical inputs are the current CDC year-to-date 2026 count, the growth trajectory of active outbreaks (Utah/Arizona, South Carolina, Texas-style), MMR coverage decline, and the market's own price history. I'll anchor on the Polymarket price, pull news on the CDC counter and outbreaks, check cross-venue markets, and run base-rate/extrapolation math.

# Current state As of the latest CDC update (~Aug 21, 2026), the U.S. has ~2,777 confirmed measles cases for 2026 YTD (some sources cite 2,566 as of Aug 13, 2,318 as of late July) — already exceeding the full-year 2025 total (2,289) and the highest since 1991. Reaching 10,000 by Dec 31, 2026 requires ~7,200+ additional cases over the remaining ~4 months, roughly double the recent weekly pace, sustained continuously. # Timeline of key events - 2025-01 to 2025-08: Southwest (Texas/Gaines County-centered) outbreak, ~750+ cases, declared over 2025-08-18. Confirmed (Wikipedia). - 2025 (full year): CDC confirms 2,289 total cases, 45 jurisdictions, 49 outbreaks — highest since 1992 pre-2026. Confirmed (CDC/Wikipedia); note earlier AAP prelim figure of 2,144 was revised upward. - 2025-11: PAHO/MRE-RVC places U.S. in "sustained with major concerns" category; Americas region loses elimination status due to Canada's endemic transmission >12 months. Confirmed (PAHO/CIDRAP). - 2026 (start): South Carolina outbreak epicenter, 600–997 cases; declared over 2026-04. Confirmed (NBC/Wikipedia). - 2026-06 onward: Utah outbreak (originated June 2025) continues, >700 cumulative, 514 in 2026. Confirmed (NBC). - 2026-07-10 to 07-30: Cases cross 2,100→2,260→2,318→2,371, surpassing 2025 full-year total; "35-year high" widely reported. Confirmed (multiple, CDC-sourced). - 2026-08 (mid): Pennsylvania and Ohio outbreaks accelerate (hundreds of new PA cases since July; 15 Ohio counties affected); Virginia (Buckingham County) reaches 129 cases. Reported (CIDRAP/NBC). - 2026-08-19 (~2 days before report): CDC adds 211 new cases in one update; CIDRAP labels outbreak "accelerating." Confirmed (CIDRAP). - 2026-08-21: YTD total 2,777; 94% of cases outbreak-associated across 36 new 2026 outbreaks. Confirmed (CDC via claude_news). - 2026-08-10: Trump signs executive order mandating MMR be split into three single-disease shots; ACIP ends routine newborn hep-B shots. Confirmed (news reports) — policy shift with uncertain near-term case impact. - Planned Nov 2026: PAHO to issue formal U.S.-specific elimination-status determination. Reported/scheduled. # Event Will cumulative CDC-confirmed 2026 U.S. measles cases reach ≥10,000 by year-end 2026? # Outcomes to forecast Yes / No (binary threshold at 10,000 cases per CDC counter) # Kalshi market anchor No direct Kalshi order-book data was returned for this ticker (kalshi_direct tool output absent). The exact-match market data available is from Polymarket (same ticker/question): **current YES price 7.4%**, 7-day trend +1.55%, 30-day trend +0.65%, price range 5.3–14.95% over 91 days, volume ~$6.5M. Treat this as the primary cross-market consensus anchor in lieu of Kalshi order book. # Sub-question answers 1. **2026 YTD count** — ~2,777 confirmed cases as of ~2026-08-21 (36 outbreaks, 94% outbreak-associated); earlier checkpoints: 2,566 (Aug 13), 2,318 (late July). [CDC/claude_news, ABC News] 2. **2024/2025 finals & historical max** — 2025 final: 2,289 cases (highest since 1991/1992). 2024 figure not directly supplied in research (gap). Historical maxima referenced: 2019 = 1,274; 1992 ≈ 2,200; 2025 now exceeds both. 3. **Active outbreaks** — South Carolina (600–997 cases, over by April 2026); Utah (ongoing since June 2025, >700 cumulative, 514 in 2026); Pennsylvania (hundreds of new cases since July, accelerating); Ohio (15 counties, growing, +211 cases in one recent week); Virginia/Buckingham County (129 cases, +19/week). Growth described as "accelerating" but 94% concentrated in specific under-vaccinated-community outbreaks rather than broad exponential community spread. [CIDRAP, NBC] 4. **Pace needed vs. 2025 peak** — Reaching 10,000 requires ~400 cases/week for remaining ~18 weeks (vs. recent observed pace ~185–211 cases/week). This is roughly 1.2–1.5× even the highest single-week peaks seen during the 2025 outbreak (est. ~170–210/week peak). [code_execution model, CIDRAP] 5. **Vaccination/policy shifts** — MMR kindergarten coverage fell to 92.4% (2025-26 school year, down from prior year, below 95% since 2019-20); exemptions rose 3.6%→4.2% (~155,000 students). Trump signed EO (2026-08-10) splitting MMR into 3 shots; ACIP ended routine newborn hep-B vaccination — both seen as risk-elevating, though RFK Jr. has publicly urged measles vaccination (rhetorical reversal). [claude_news] 6. **Elimination status / forecasts** — Americas region (incl. US/Canada) lost elimination status per PAHO Nov 2025; US placed in "sustained with major concern" category; Lancet/CIDRAP analysis says US "highly likely" to formally lose status in 2026, with PAHO's US-specific decision due Nov 2026. No CDC numeric 2026 forecast found (gap); experts (Nuzzo, Besser) call it the "deadliest outbreak in decades" but don't quantify. 7. **Related markets on lower thresholds** — None found on Polymarket (0 matches) or Kalshi (0 direct matches); only a tangential Kalshi market "avg measles cases during Trump's term ≥5000" priced at 32% (down 6pp in 7 days) — not directly comparable given different metric/timeframe. # Key facts (high-confidence, factual) 1. [CDC/claude_news] 2026 YTD ≈2,777 cases as of 2026-08-21. 2. [CDC/Wikipedia] 2025 full-year total = 2,289 cases, highest since 1991. 3. [CIDRAP] Recent single-update jump of +211 cases signals accelerating, not decelerating, trend. 4. [claude_news] 93-94% of cases are unvaccinated/unknown-status individuals in outbreak clusters. 5. [PAHO/CIDRAP] Americas lost elimination status Nov 2025; US-specific determination pending Nov 2026. # Cross-market signals - Kalshi related: Distinct market "avg cases during Trump's term ≥5000" at 32% — not a direct proxy. - Polymarket (same market): 7.4% YES, slight upward drift over 30 days, high liquidity ($6.5M volume) suggesting well-calibrated market. - No sportsbook data available. # Analyst opinions and speculation - CIDRAP/Lancet analysts: US "highly likely" to lose elimination status in 2026, but this is separate from hitting 10,000 cases. - Epidemiologists (Nuzzo, Besser): warn of "deadliest outbreak in decades," expect continued spread from travel/large events, but no explicit 10,000 prediction. - code_execution Monte Carlo models (lognormal vs. negative-binomial mixture): P(≥10,000) ≈ 1–5%, though built on a stale/incorrect low YTD placeholder (200 cases) rather than actual ~2,777 — results should be treated as illustrative of methodology, not a precise updated estimate; a re-run with actual YTD and current weekly pace (~200/week) would likely still yield low-single-digit-to-high-single-digit percentage probability given the ~2x pace acceleration needed sustained for 4+ months. # Directional lean per outcome - **Yes (≥10,000)**: Supported by record-breaking pace, multiple simultaneous active outbreaks (PA, OH, UT, VA), declining MMR coverage/rising exemptions, adverse vaccine policy shifts, and accelerating recent weekly additions (+211 in one CIDRAP update). Opposed by: current trajectory implies year-end total more likely in 4,000–6,000 range absent a new large concentrated outbreak; outbreaks remain clustered in specific low-vaccination communities rather than broad community transmission; required pace (~400/week) exceeds even 2025's worst single-week (~200/week) by ~2x, sustained for months — historically unprecedented in the elimination era. - **No (<10,000)**: Supported by market pricing (7.4% Yes), Monte Carlo estimates (1-5%), and current pace math showing a ~2x sustained acceleration is needed. Opposed by: genuine tail risk from declining coverage, policy deregulation, and multiple concurrent accelerating outbreaks that could compound. # Gaps / unknowns - No verified 2024 CDC total supplied. - No live Kalshi order-book (kalshi_direct) data for this specific ticker was returned. - code_execution simulation used a placeholder/stale YTD figure (200), understating current YTD (~2,777) — numeric probability outputs are unreliable as stated. - No official CDC 2026 year-end case forecast located. # Calibration anchors - Polymarket YES price (exact-match ticker): 7.4%, range 5.3–15% over past 91 days. - Historical precedent: worst year since elimination (2025) reached only 2,289; prior worst modern year 2019 = 1,274. No year has approached 10,000 since pre-elimination era (1992 ≈2,200 was already an outlier low relative to threshold).

1. Both forecasts heavily anchor on the Polymarket 7.4% price and converge to nearly identical 7-8% estimates, but neither independently stress-tests whether that market price itself might be stale or mispriced given the brief notes "no live Kalshi order-book data" and the Monte Carlo model used a stale placeholder (200 cases) — both forecasters essentially defer to a single external number rather than triangulating independently, producing false confidence via anchoring rather than genuine convergence. 2. Neither forecast explicitly addresses the seasonality argument consistently: Forecast 1 raises that measles "typically slows in autumn and peaks in late winter/spring" as a factor working against acceleration, but this actually cuts both ways since a spring 2027 peak wouldn't count for the 2026 cutoff, while an unmentioned possibility is a late-year holiday-travel/school-return surge (Nov-Dec) that could concentrate cases faster than the flat weekly-average math assumes — the linear pace requirement (~400/week) may understate tail risk from a sudden new large outbreak (as happened with South Carolina and Utah) rather than gradual compounding of existing ones. 3. Both forecasts underweight the accelerating trend signal: the brief notes "+211 new cases in one update" and CIDRAP explicitly labels the outbreak "accelerating," yet both forecasters use the trailing average (185-211/week) as the baseline pace without adjusting for the possibility that the acceleration itself continues, which would meaningfully shift required incremental acceleration downward from "2x sustained" to something more achievable if the trend continues nonlinearly. 4. Neither forecaster discusses the policy-shift uncertainty in depth — the Aug 10, 2026 executive order splitting MMR into three shots and ending routine newborn hep-B vaccination is a genuinely novel policy shock with no historical precedent for near-term case impact; both treat it as a minor "counterweight" without considering scenarios where reduced vaccine uptake compounds within the exact remaining Sep-Dec window, which is the only near-term test of this policy's effect. 5. Both forecasters similarly discount the multi-outbreak compounding scenario (PA, OH, UT, VA simultaneously accelerating) as insufficient to reach threshold, but neither quantifies what combined growth rates across 4+ concurrent accelerating outbreaks would need to look like — this is a distinct tail scenario (multiplicative outbreak interaction/import-and-spread across states) that differs from the "one dominant outbreak" reference class (2025 Southwest, 2026 South Carolina) used implicitly for the "2x historical peak" framing. 6. Confidence levels (0.75 and 0.68) seem arbitrarily assigned without clear justification tied to evidence quality — given identical reasoning and near-identical probability estimates, the differing confidence scores are not explained by any substantive disagreement in the rationales, suggesting the confidence metric here is not doing meaningful diagnostic work.

7% (72% confidence)

Yes: 7% No: 93%

Reaching 10,000 requires ~7,200 additional confirmed cases in the remaining ~19 weeks (~380/week), roughly double the observed recent pace of ~185-211/week and about 2x the worst weekly peaks of the record 2025 outbreak, sustained continuously through a seasonally weaker autumn window. The devil's advocate is right that the acceleration signal (+211 in one update, four concurrent outbreaks, 92.4% kindergarten MMR coverage, and a novel vaccine-policy shock) creates a genuinely fat right tail — but vaccine-policy changes made in August 2026 cannot plausibly translate into susceptibility-driven case surges by December, and epidemic doubling of the national weekly rate has no elimination-era precedent. The exact-match Polymarket contract with $6.5M volume prices YES at 7.4% with only mild upward drift, and independent pace math plus outbreak-clustering structure (94% outbreak-associated in defined under-vaccinated communities, not broad community transmission) corroborate rather than merely echo that price. I settle at 7%, essentially at the market and both forecasters, with the tail-risk arguments preventing me from going lower toward the 1-5% Monte Carlo range.

Total pipeline time: 296.5s